Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.
In season 1, episode 1 of Targeted Talks, community physician Jason R. Williams, MD, DABR, interventional radiologist, Williams Cancer Institute, leads a discussion with George R. Simon, MD, FACP, FCCP, medical oncologist, The University of Texas MD Anderson Cancer Center, about the use of immunotherapy in patients with non–small cell lung cancer (NSCLC), whether treated in an academic or community setting, and how this could be challenged with the discovery of a genetic driver alteration.
During the discussion, the 2 experts cover the pros and cons of immunotherapy use and how they differ in the community setting versus the academic setting, the available tools for profiling patients, promising immune checkpoint inhibitors for the treatment of NSCLC, key genetic drivers in NSCLC, and choosing the optimal subsequent therapy for patients with NSCLC.
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC
April 7th 2024An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
April 5th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More